Studies of TAM depletion strategies with limited efficacy in most cancers, including CSF1/CSF1R inhibitors (e.g., PLX3397), showed limited monotherapy efficacy, except in CSF1R-driven tumors, like diffuse-type giant cell tumors [52]. This evidence concerns the gene CSF1 and cancer.